News

Press

January 7, 2026

Labcorp

Labcorp is a global leader of innovative and comprehensive laboratory services. The company’s Venture Fund invests in and supports early stage, private companies that are focused on improving health outcomes through innovative offerings aimed at making healthcare more convenient, accessible, data-driven and personalized.

November 18, 2025

Viz AI Partnership

Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a strategic partnership with IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions. This collaboration expands Viz.ai’s pulmonary portfolio and introduces new AI capabilities that can assess for interstitial lung findings compatible with interstitial lung disease (ILD).

October 20, 2025

Virtual Bronch

The IMVARIA team conducted the pivotal VIRTUAL-BRONCH study of its new Bronchosolve solution to obtain data that underscores efficacy. In this study focused on better non-invasive diagnosis of lung cancer in cases of suspicious pulmonary nodules, topline results showed increased correct cancer classification independently and in combination with expert radiologists and pulmonologists.

September 3, 2025

NIH Sbir

IMVARIA was selected for this NIH SBIR grant because of our innovative technology, two prior FDA authorizations, growing commercial traction, a strong interdisciplinary team, and a unique go-to-market strategy. Together, these factors demonstrate scientific credibility and a clear path to enhancing patient care,” said Joshua Reicher, MD, Co-founder and CEO of IMVARIA. “Our Fibresolve AI adjunctive diagnostic service is already making a real difference in patients’ lives, giving us the confidence to apply it to other challenging problems, including oncology assessment.

June 10, 2025

Medical Horizons

The introduction of IMVARIA to the MENA region will give pulmonologists a powerful adjunct tool to help with verifying a diagnosis or ruling out ILD or IPF in a non-invasive manner,” said Guido Osti, CEO at Medical Horizons. “IMVARIA’s AI innovation complements the clinical decision-making that pulmonologists engage in every day. It adds another tool in the pulmonologist’s toolbox, making AI work for them.

May 18, 2025

Imvaria ATS25

IMVARIA’s Fibresolve received FDA authorization in early 2024 and has gone through a rigorous process to make it useful and reliable for pulmonologists. Fibresolve is available through IMVARIA’s centralized service that uses AI to help guide safe, non-invasive diagnoses. Fibresolve also has the distinction as the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association (AMA) in any disease.